Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Avacta Group plc ( (GB:AVCT) ) has shared an announcement.
Avacta Group plc announced a promising partial response in a patient with metastatic salivary gland cancer during the dose expansion phase of its FAP-Dox (AVA6000) Phase 1b trial. This development is significant given the high unmet need for effective treatments in this rare cancer type, which lacks a preferred standard therapy. The company plans to release final data from the AVA6000 Phase 1a trial later in 2025 and will provide a business update at its upcoming Annual General Meeting.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £40.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
More about Avacta Group plc
Avacta Therapeutics is a clinical-stage life sciences company focused on developing highly potent cancer therapies using its proprietary pre|CISION® platform. This platform is designed to deliver targeted oncology drugs by concentrating potent warheads in the tumor microenvironment while sparing normal tissues. Avacta’s pipeline includes pre|CISION® peptide drug conjugates and Affimer® drug conjugates, offering unique advantages over traditional antibody drug conjugates.
Average Trading Volume: 1,740,301
Technical Sentiment Signal: Sell
Current Market Cap: £116M
See more insights into AVCT stock on TipRanks’ Stock Analysis page.